Purchase this article with an account.
Don Minckler, Trabectome Study Group; Update on Outcomes of Trabectome. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3175.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To update the outcomes of Trabectome surgical procedures
A total of 3242 patients that underwent Trabectome alone or Trabectome combined with cataract surgery were included. All patients had at least 3m of follow-up. Outcome measures included IOP, number of glaucoma medications and secondary surgery, if any. The success for Kaplan Meier survival analysis was defined as IOP ≤ 21mmHg, IOP reduced by 20% or more from baseline on any two consecutive visits after 3 month, and no secondary glaucoma surgery.
Trabectome+Phaco (n=1439): The mean pre-operative IOP at baseline was 20.5±7.1mmHg and reduced to 15.6±3.6 mmHg (p<0.01) at 12 months and 15.6±3.9 mmHg (p<0.01) at 24months. Number of medications was reduced from 2.3±1.2 to 1.6±1.3 (p<0.01) and 1.9±1.3 (p<0.01) at 12, 24 month respectively. Survival rate was 97% and 94% at 12m and 24m. 32 patients (2%) required secondary surgery by 24 months. Trabectome Alone (n=1804): The mean pre-operative IOP at baseline was 25.0±7.9mmHg and reduced to 16.7±4.2 mmHg (p<0.01) at 12 months and 17.0±5.0 (p<0.01) at 24months. Number of medications was reduced from 2.9±1.3 to 2.2±1.3 (p<0.01) and 2.1±1.4 (p<0.01) at 12, 24 month respectively. Survival rate was 84% and 73% at 12m and 24m. 264 patients (15%) required secondary surgery by 24 months.
Both Trabectome with cataract surgery and Trabectome alone seem to be effective and safe for glaucoma patients.
This PDF is available to Subscribers Only